The largest database of trusted experimental protocols

7 protocols using magnetic serum plasma dna maxi kit

1

Extracting and Detecting cfDNA from Urine and Tumor Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Magnetic Serum/Plasma DNA Maxi Kit (cat DP710-02, Tiangen Biotechnology, China) was used to extract urinary cfDNA from collected urine supernatant according to the manufacture’s instruction. The Blood/Cell/Tissue Genomic DNA Extraction Kit (cat DP304, Tiangen Biotechnology, China) was used to extract DNA from the collected tumor tissues or urine supernatant according to the manufacture’s instruction. The DNA was stored at −80 °C until using. The Multiplex I cfDNA Reference Standard Set (HorizonDx), including with 8 mutations at 5%, 1%, and 0.1% allelic frequencies were used to perform the cf-SUPER study.
+ Open protocol
+ Expand
2

Cell-free DNA Extraction from Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell-free DNA was extracted from the plasma samples (0.1 mL/mouse sample; 0.6 mL/goat sample) with a Magnetic Serum/Plasma DNA Maxi Kit (Tiangen Biotech, Beijing, China). Worm genomic DNA was extracted with the TIANamp Genomic DNA Kit (Tiangen Biotech), according to the manufacturer’s protocol. All of the extracted DNA samples were stored at −20 °C.
+ Open protocol
+ Expand
3

Targeted DNA Sequencing of Tumor-Driver Genes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was extracted from tissue specimens and peripheral blood mononuclear cells (PBMCs) using standard methods. A commercially available gene panel—Mygenostics Tumor Driver (MyGenostics, Beijing, China)—was applied to perform targeted DNA sequencing. Briefly, targeted genes were enriched using a biotinylated capture probe (MyGenostics, Baltimore, MD, USA) [21 (link)] and sequenced using the Illumina NextSeq500 platform (Illumina, San Diego, CA, USA). The panel contained 301 tumor-driver genes with an average effective sequencing depth above 1000X. A complete list of the tested genes is provided in Additional file 1. Circulating cfDNA was extracted using Magnetic Serum/Plasma DNA Maxi Kit (Tiangen Biotech, Beijing, China). Barcode-assisted target enrichment was performed, followed by polymerase chain reaction (PCR). The same 301 genes as the panel used for tissue were sequenced with the Illumina NextSeq500 platform.
+ Open protocol
+ Expand
4

Quantitative Analysis of Protein Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Reagents included antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (cat. no. KC-5G4; Aksomics, Shanghai, China), antibone morphogenetic protein receptor type 1A (BMPR1A) antibody (cat. no. 12702-1-AP; Proteintech, IL, USA), antimitogen-activated protein kinase kinase kinase 1 (MAP3K1) antibody (cat. no. 19970-1-AP; Proteintech, IL, USA), Magnetic Serum/Plasma DNA Maxi Kit (Tiangen, Beijing, China), TRIzol reagent (Invitrogen, CA, USA), PrimeScript RT kit, and SYBR Premix Ex Taq II (Takara, Shiga, Japan). Instruments included an optical microscope, an inverted microscope and imaging system (Olympus, Tokyo, Japan), and an ABI 7900 real-time PCR system (Applied Biosystems, MA, USA).
+ Open protocol
+ Expand
5

Targeted NGS for ctDNA Profiling in GTN

Check if the same lab product or an alternative is used in the 5 most similar protocols
cfDNA was prepared from 3 mL plasma according to the manufacturer's instructions using a Magnetic Serum/Plasma DNA Maxi Kit (Tiangen). cfDNA was quantified using an Agilent 2100 Bioanalyzer (Agilent, CA, USA). We used a targeted NGS panel (MyGenostics, Beijing, China) in this study, which included 559 genes reported to be associated with oncogenesis, progression, and targeted therapy (Supplementary ). Whole exome sequencing of the 559 genes was performed to identify gene alterations in ctDNA from patients with GTN with a target region sequencing depth of more than 500x. DNA from paired peripheral blood mononuclear cells of the same patient was sequenced as the germline control.
+ Open protocol
+ Expand
6

Microbial DNA Extraction from Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols
Microbial cellular DNA was extracted from whole blood using a MolYsis Complete5 kit (Molzym GmbH), according to the manufacturer's instructions. This kit provides all the ingredients for the lysis of human and animal cells, degradation of human and animal DNA, degradation of the cell wall of gram‐positive and gram‐negative bacteria, removal of PCR inhibitors, and microbial cellular DNA purification. Microbial cellular DNA was eluted in 100 μL of the elution buffer provided by the kit. To further concentrate the microbial cellular DNA, 100 μL of the eluted cellular DNA was processed using a ZYMO DNA Clean and Concentrator™ kit (ZYMO Research), finally yielding 30 μL of microbial cellular DNA. The cellular DNA was used or stored at −80°C until required.
Microbial cfDNA was extracted from 8 mL of whole blood collected in a cfDNA preservative tube using Cell‐Free DNA BCT® (Streck). The extraction was performed using the Magnetic Serum/Plasma DNA Maxi Kit (Tiangen Biotech). Briefly, plasma was immediately isolated by centrifugation of whole blood at 1600 g at 22°C for 20 min. Four millilitres of the supernatant were used for cfDNA extraction. The eluted cfDNA was stored at −80°C until required.
+ Open protocol
+ Expand
7

Metagenomic Analysis of Respiratory Specimens

Check if the same lab product or an alternative is used in the 5 most similar protocols
First, DNA and RNA were extracted using Magnetic serum/plasma DNA Maxi kit (Tiangen Biotech (Beijing) Co. Ltd., China). For BALF specimens, HostZERQ Microbial DNA kit (Jianshi Biotech (Beijing) Co. Ltd., China) was used to remove human nucleic acids for further nucleic acid extraction. Second, nucleic acids were fragmented into 150–300 bp in length with Bioruptor (Diagenode Diagnostics, Belgium) that is a non-contact ultrasonic disruptor. The library was constructed using Library Preparation kit (Kapabio System, Boston, MA). Third, high-throughput sequencing was conducted with Illumina Next Seq550Dx system (Illumina Inc., San Diego, CA). In the process of sequencing, adaptors, reads with low quality and repeated sequences, and short reads < 36 bp in length were removed. Microorganisms were then identified in the specimens through sequence alignment in the microbial genome database (bacteria, viruses, fungi and parasites) by using Bowtie2 (version 2.3.5) (Genoxor Medical Science and Technology Inc., Shanghai) [24 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!